"At this time, I cannot recommend using andexanet alfa until further evidence shows both safety and efficacy in patient-oriented outcomes."
@srrezaie#FOAMed
https://t.co/Ilr8kCbf9b
Now that we can be sure andexanet alfa works, does it work better than standard of care? And will its efficacy be worth the astronomical price tag? The forthcoming RCT will be illuminating. https://t.co/2y5eoxelyz
@VPplenarysesh While I’m enthusiastic about the potential for “prevention of progression” of clonal disorders I think we have to be super careful about not adding unjustified expense, burden and toxicity - as well as making a huge swath of happy healthy people into worried “precancer patients”